Latest News
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance
Quarterly Activity Report – Quarter Ending 31 December 2022
Highlights: Imagion presented results from MagSense® HER2 Phase I study at global breast cancer meeting showing safety and detectability Tasks expert panel of radiologists with
Imagion presents MagSense® interim study results at breast cancer meeting
Imaging agent aids in resolving nodal status MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of
Quarterly Activity Report – Quarter Ending 30 September 2022
Highlights: Imagion presented prostate cancer research data at World Molecular Imaging Conference (WMIC) Receipt of $2.5 million R&D tax incentive (post-quarter end) MELBOURNE – Imagion
Imagion Biosystems receives AU$2.5 million in R&D tax incentives
ASX Announcement: MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report
The Market Herald Interview Discussing First-of-its-Kind Magnetic Imaging Technology
We recently announced that our MagSense® diagnostic technology has the potential to target prostate cancer tumors, making this the second cancer type the technology has
Fear and Greed Podcast Discussing Precise Imaging Solutions to Detect Cancers
Our Chairman and CEO Bob Proulx was a recent guest at the Fear and Greed podcast, discussing our pursuit of better, more precise imaging solutions to
2022 Switzer Small & Micro Cap Conference Presentation
Imagion Bio CEO, Robert Proulx, presents company information to investors at the 2022 Switzer Small & Micro Cap Conference in September. Video Transcript: Thank you,
Imagion to Present Prostate Cancer Research Data at WMIC 2022
Imagion to present prostate cancer research data at World Molecular Imaging Congress MagSense® molecular imaging agent shows high specificity and selectivity MELBOURNE — Imagion Biosystems
Half-Year Results for the First Half of 2022 and Appendix 4D
Today, we released our Appendix 4D and Half-Year Financial Report for the half-year ending 30 June 2022 to the ASX. 1H2022 Highlights: MagSense® HER2 breast
Quarterly Activity Report and Appendix 4C for 30 June 2022
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 30 June 2022. The announcement highlights: MagSense® HER2 imaging agent
Iron Oxide Nanoparticles in Lipid Delivery System May Lead to Better Cancer Treatment
Lipids are frequently used to form drug carrying nanoparticles because of their favorable biocompatibility. However, construction of such drug-carrying lipid nanoparticles often involves multiple steps.
Q&A Session at 2022 Annual General Meeting
Imagion Biosystems recording of the Q&A session at the 2022 Annual General Meeting. Imagion Biosystems’ board of directors answer questions from shareholders at the AGM
Results of 2022 Annual General Meeting
In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, Imagion Biosystems Limited advises the results of its Annual General
Presentation Visuals from 25th May 2022 Annual General Meeting
The presentation visuals from the 25th May 2022 Annual General Meeting are now available. You can find the 2022 AGM Investor Presentation here.
Chairman’s Address to Shareholders at 2022 Annual General Meeting
Imagion Biosystems recording and transcript of the Chairman’s address to shareholders at the 2022 Annual General Meeting. Dear Shareholders, It is my pleasure to welcome
Health Industry Hub Interview
Bob Proulx sat down with Rozalina Sarkezians, Managing Director & Founder of Health Industry Hub, for a chat about Imagion Biosystem’s work developing our breakthrough
Quarterly Activity Report and Appendix 4C for 31 Mar 2022
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 31 March 2022. The announcement highlights: MagSense® HER2 breast cancer
Imagion Biosystems April 2022 Investor Newsletter
We are pleased to provide our investors with our April 2022 Investor Newsletter. In this edition, our Chief Financial Officer, Geoff Hollis, gives a recap
Employee Spotlight: Dan Inglese, Research Associate
Highlighting our dedicated employees who bring both their experience and passions to Imagion Biosystems: What experience do you bring prior to joining IB? I
MagSense® HER2 Breast Cancer First-in-human Study Progress Update
Imagion Biosystems Limited (ASX: IBX) is pleased to provide an update on the progress of its first-in-human study for the MagSense® HER2 breast cancer imaging
Imagion Biosystems 2021 Full Year Results
Imagion Biosystems has released its Annual Report for the year ended 31 December 2021. See linked documents below. 2021 Clinical Highlights: Multiple patients enrolled and
Quarterly Activity Report and Appendix 4C for 31 December 2021
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 31 December 2021. The announcement highlights a recap of the
Imagion Bio at The Edison Open House: Global Healthcare 2022
Our CEO, Bob Proulx, connected with the Edison Group during their Global Healthcare Open House to discuss in detail, the nanotechnology behind our bio-imaging MagSense technology
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.